Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10590MR)

This product GTTS-WQ10590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3302MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ9019MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ514MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ2333MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ83MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ3660MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ13973MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4304MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW